Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Amsterdam University Medical Centers · Institute of Infection and Immunity · +7 more institutions
Abstract
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that…
Citation impact
- FWCI
- 30.50
- Percentile
- 100%
- References
- 57
Authors
33- PJPhilip J. M. BrouwerCorresponding
Amsterdam University Medical Centers, Institute of Infection and Immunity
- TGTom G. CanielsCorresponding
Amsterdam University Medical Centers, Institute of Infection and Immunity
- KVKarlijn van der StratenCorresponding
Amsterdam University Medical Centers, Institute of Infection and Immunity
- JLJonne L. Snitselaar
Amsterdam University Medical Centers, Institute of Infection and Immunity
- YAYoann Aldon
Amsterdam University Medical Centers, Institute of Infection and Immunity
Topics & keywords
- Coronavirus disease 2019 (COVID-19)
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- 2019-20 coronavirus outbreak
- Virology
- Antibody
- Vulnerability (computing)
- Neutralizing antibody
- Betacoronavirus
- Good health and well-being